Sean Dalziel Consultant

Sean Dalziel


Chief Scientific Officer & Corporate Development Manager

Sean is an Australian born, scientific entrepreneur and is the Managing Director of Cleo Life Sciences, a CMC consulting and drug product development firm with operations in San Francisco USA, and Brisbane Australia. His business leadership skills include venture initiation, market planning, corporate development, due diligence (licensing, M&A, integration), and strategic partnerships.

He is a contributor and leader in the CMC development of 5 commercial drugs, including late-stage development and NDA/EUA support to LagevrioTM (molnupiravir, Ridgeback Biotherapeutics/Merck), Kyprolis® (carfilzomib, Onyx Pharmaceuticals), Vibativ® (telavancin, Theravance), OxbrytaTM (voxelotor, Global Blood Therapeutics), and early development CMC support to Yupleri® (revefenacin, Theravance). He has supported CMC aspects of over 35 clinical staged IND/IMPD drug candidates, including 5 currently in registration trials across oncology, RSV, auto-immune, and NASH indications.

Sean’s technology leadership expertise includes CMC, strategic planning and project execution, manufacturing process and supply chain development (drug substance and drug product), technology transfer, scale-up and cGMP operations, validation, commercialization and CMC regulatory affairs with global health authorities. He has strong scientific and engineering research skills applied across oral, injectable, and inhaled dosage forms. Sean contributed to inhaled drug development at Theravance (Innoviva, Inc.) during the Strategic Alliance with GSK, now with a commercial DPI portfolio including Breo®, Anoro®, and Trelegy®. At DuPont, Sean contributed to particle engineering and device technologies for DPI and Dymel® propellant MDI products.

Sean is an executive consultant and serves on development advisory boards for a number of biopharmaceutical companies. Previously, he was VP Head of Technical Operations at Tobira Therapeutics, and at Onyx Pharmaceuticals, Head of Pharmaceutical Sciences at Theravance, and held roles of increasing responsibilities at DuPont, and CSIRO. Sean’s academic degrees include: PhD (Chem. Eng. University of Queensland), MBA (UC Berkeley), BAppSc (Hons, Food Tech, University Western Sydney), and BSc (Chemistry and Molecular Biology, University of Sydney).